drugset / Trial / NCT07182565
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the safety and efficacy of HFRT plus neoadjuvant ICT in locally advanced resectable GEJA.
Timeline
- Start
- 2025-11-18
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 40 mg | Oral |
| Subject | S-1 | Small molecule | 50 mg | Oral |
| Subject | S-1 | Small molecule | 60 mg | Oral |
| Subject | Serplulimab | Monoclonal antibody | 300 mg | Intravenous |